Catalent to buy Paragon Bioservices for $1.2 billion: WSJ


(Reuters) – Drug developer Catalent Inc has agreed to buy privately held Paragon Bioservices Inc for $1.2 billion (917.64 million pounds), the Wall Street Journal reported on Sunday, citing people familiar with the matter.

An all-cash deal between the companies is expected to be announced on Monday morning, the Journal said.

Reporting by Ismail Shakil in Bengaluru; Editing by Chris Reese



READ SOURCE

READ  Women should be offered cancer checks during work breaks and while shopping to boost uptake, a review says

LEAVE A REPLY

Please enter your comment!
Please enter your name here